Estados Unidos - inglês - NLM (National Library of Medicine)

dharma research, inc. - aluminum chloride (unii: 3cyt62d3ga) (aluminum cation - unii:3xhb1d032b) - aluminum chloride 8.75 g in 35 g - - soak a cotton tipped applicator with frenna ac. - apply to bleeding area with pressure until bleeding is stopped. should a small dark coagulum appear, flush it away with water. this will have no effect on hemostatic action. - remove the impregnated cord from sulcus. - flush with water and dry with air. if hemostasis is not achieved, repeat application. - rinse with water and air dry until bleeding is no longer present. frenna ac is a topical astringent solution of aluminum chloride. gingival retraction can be achieved using a plain gingival retraction cord moistened with frenna ac. stops gingival bleeding fast. if you should anadvertently damage the gingival margin during tooth preparation or while placing a strip, a band, or a cervical matrix, moisten the area with frenna ac which will control and stop bleeding quickly. frenna ac contains no epinephrine. the use of casoconstrictors for gingival retractions and bleeding is potentially dangerous and should be avoided. a plain gingival retraction cord can be

Estados Unidos - inglês - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - ethynodiol diacetate (unii: 62h10a1236) (ethynodiol - unii:9e01c36a9s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - ethynodiol diacetate 1 mg - ethynodiol diacetate and ethinyl estradiol tablets usp, 1 mg/35 mcg are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization and progestogen implants and injections, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year  ‡ method (1) typical use § (2) perfect use ¶ (3) (4) chance # 85 85 spermicides Þ 26 6 40 periodic abstinence 25 63    calendar 9    ovulation method 3    sympto-thermal ß 2    post-ovulation 1 withdrawal 19 4 cap à    parous women 40 26 42    nulliparous women 20 9 56 sponge    parous wo

Estados Unidos - inglês - NLM (National Library of Medicine)

wg critical care, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 1 g in 100 ml - magnesium sulfate in 5% dextrose injection, usp is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the effect of intravenous magnesium on milk production is unknown. the developmental and health benefits to the neonate of breastfeeding should be considered along with the mother's clinical need for magnesium sulfate in 5% dextrose injection and any potential adverse effects on the breastfed infant from magnesium sulfate in 5% dextrose injection or from the underlying maternal condition. the safety and effectiveness of magnesium sulfate in 5% dextrose injection have been established for the prevention of eclampsia in adolescents with preeclampsia and the treatment of seizures and prevention of recurrent seizures in adolescents with eclampsia. dosing recommendation in pregnant adolescent patients are the same as for pregnant adult patients [see dosage and administration (2.2)] . magnesium is excreted solely by the kidneys. patients with severe renal impairment (urine output less than 100 ml per 4 hours) are at greater risk for increased magnesium concentrations that may lead to magnesium toxicity [see warnings and precautions (5.2) and clinical pharmacology (12.3)] . in patients with severe renal impairment, dosage reduction is recommended and the maximum recommended dosage is lower than patients with normal renal function [see dosage and administration (2.3)] .

Estados Unidos - inglês - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Estados Unidos - inglês - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium (mg++ ) level is usually below the lower limit of normal (1.5 to 2.5 meq/liter) and the serum calcium (ca++ ) level is normal (4.3 to 5.3 meq/liter) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection, usp is also indicated for the prevention and control of seizures (convulsions) in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Estados Unidos - inglês - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 10 mg in 1 ml - magnesium sulfate in 5% dextrose injection is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the

Estados Unidos - inglês - NLM (National Library of Medicine)

cardinal health - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in a pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Estados Unidos - inglês - NLM (National Library of Medicine)

dentsply llc, professional division trading as "sultan healthcare" - aluminum chloride anhydrous (unii: lif1n9568y) (aluminum cation - unii:3xhb1d032b) - aluminum chloride anhydrous 250 mg in 1 g - indicated for the control of minor hemorrhage during dental restorative procedures. this product should not be used with individuals with known sensitivities to aluminum chloride.

Estados Unidos - inglês - NLM (National Library of Medicine)

bryant ranch prepack - diclofenac potassium (unii: l4d5ua6cb4) (diclofenac - unii:144o8ql0l1) - diclofenac potassium 50 mg - carefully consider the potential benefits and risks of diclofenac potassium tablets and other treatment options before deciding to use diclofenac potassium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ; gastrointestinal bleeding, ulceration, and perforation ). diclofenac potassium tablets are indicated: - for treatment of primary dysmenorrhea - for relief of mild to moderate pain - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis diclofenac is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see warnings ; anaphylactic reactions, serious skin reactions ). - history of asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported i

Estados Unidos - inglês - NLM (National Library of Medicine)

hospira, inc. - sodium acetate anhydrous (unii: nvg71zz7p0) (acetate ion - unii:569dqm74sc, sodium cation - unii:lyr4m0nh37) - sodium acetate anhydrous 164 mg in 1 ml - sodium acetate injection, usp (2 meq/ml) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. sodium acetate injection, usp (2 meq/ml) is contraindicated in patients with hypernatremia or fluid retention.